[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 69 of about 69
1. Friedrich RE, Giese M, Li L, Schenk Y, Schmelzle R: Diagnosis, treatment and follow-up control in 124 patients with basal cell carcinoma of the maxillofacial region treated from 1992 to 1997. Anticancer Res; 2005 May-Jun;25(3A):1693-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis, treatment and follow-up control in 124 patients with basal cell carcinoma of the maxillofacial region treated from 1992 to 1997.
  • AIM: The aim of this study was to analyze diagnostic and therapeutic procedures and the outcome of patients treated for the most common malignant tumor of the facial skin, basal cell carcinoma.
  • PATIENTS AND METHODS: The files of patients with basal cell carcinoma (BCC) treated over a period of 6 years were evaluated.
  • RESULTS: One-hundred and twenty-four patients were treated for 216 basal cell carcinomas (solitary: 67%, multiple: 33%).
  • Local recurrences occurred in 14 patients, predominantly within the first year after ablative surgery.
  • CONCLUSION: Basal cell carcinoma is a malignant tumor, slowly growing and often showing wide extension to macroscopically non-affected sites.
  • The sclerodermiform subtype is prone to local recurrence and these patients should be followed up carefully.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Face / pathology. Jaw / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033084.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


2. Ozolins M, Williams HC, Armstrong SJ, Bath-Hextall FJ: The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma. Trials; 2010 Apr 21;11:42
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma is the commonest human cancer.
  • To compare excisional surgery with imiquimod cream for nodular or superficial basal cell carcinoma in low risk sites, with respect to 3 year clinical clearance, cost-effectiveness and cosmetic results.
  • METHODS/DESIGN: Five hundred participants with low risk nodular or superficial basal cell carcinoma will be recruited from hospitals to this multi-centre, randomised, parallel group, controlled phase III trial.
  • Treatment in the imiquimod group is for 6 weeks for superficial basal cell carcinoma and 12 weeks for nodular basal cell carcinoma.
  • Primary outcome variable: the proportion of participants with clinical evidence of success (no recurrence) at 3 years.
  • Secondary outcomes include: i) clinical success at 1, 2 and 5 years, ii) time to first recurrence, iii) cosmetic appearance of lesion site after treatment, iv) level of pain, and v) cost-effectiveness.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / surgery. Skin Neoplasms / drug therapy. Skin Neoplasms / surgery
  • [MeSH-minor] Administration, Cutaneous. Cost-Benefit Analysis. Drug Costs. Female. Genotype. Health Care Costs. Humans. Male. Ointments. Patient Satisfaction. Phenotype. Polymorphism, Genetic. Prospective Studies. Recurrence. Research Design. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 1999 Sep;141(3):415-23 [10583044.001]
  • [Cites] Br J Dermatol. 2009 Oct;161(4):840-5 [19438849.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):807-13 [11312429.001]
  • [Cites] Am J Epidemiol. 2004 Apr 1;159(7):702-6 [15033648.001]
  • [Cites] J Dermatol Surg Oncol. 1986 Aug;12(8):860-5 [3734238.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] J Am Acad Dermatol. 1991 Jan;24(1):1-13 [1999506.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23):1649-62 [1435901.001]
  • [Cites] Br J Dermatol. 1994 Dec;131(6):914-5 [7857854.001]
  • [Cites] Arch Dermatol. 1997 May;133(5):593-6 [9158412.001]
  • [Cites] Arch Dermatol. 1999 Oct;135(10):1177-83 [10522664.001]
  • [Cites] Arch Dermatol. 1999 Oct;135(10):1255-9 [10522675.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(1):CD003412 [17253489.001]
  • [Cites] Int J Cancer. 2007 Nov 1;121(9):2105-8 [17640064.001]
  • [Cites] J Clin Epidemiol. 2009 May;62(5):464-75 [19348971.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • (PMID = 20409337.001).
  • [ISSN] 1745-6215
  • [Journal-full-title] Trials
  • [ISO-abbreviation] Trials
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN48755084; ClinicalTrials.gov/ NCT00066872
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; P1QW714R7M / imiquimod
  • [Other-IDs] NLM/ PMC2877028
  •  go-up   go-down


3. Clouser MC, Roe DJ, Foote JA, Harris RB, Alberts DS: Dose response of retinol and isotretinoin in the prevention of nonmelanoma skin cancer recurrence. Nutr Cancer; 2010;62(8):1058-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose response of retinol and isotretinoin in the prevention of nonmelanoma skin cancer recurrence.
  • Using data from a randomized, double blind, study of the efficacy of retinol or isotretinoin vs. placebo on recurrence of nonmelanoma skin cancer in high-risk subjects, a reanalysis of the original intent to treat analysis was performed in a dose-response format.
  • Cox proportional hazards models describe the relationship between dose quartiles of isotretinoin and retinol use and time to first occurrence of squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) in crude and adjusted models.
  • Neither the isotretinoin nor retinol models showed any significance at any quartile for reduction in first BCC or SCC occurrence.
  • Crude and adjusted retinol models show a statistically significant increase in risk of developing an SCC in the first quartile, whereas only the crude model shows a statistically significant increase in risk in the first quartile of the isotretinoin model.
  • For retinol and SCC, hazard ratios (HRs) for the first quartile were as follows: HR = 2.92, 95% confidence interval (CI) = 1.67-5.10 crude; HR = 1.95, 95% CI = 1.00-3.80 adjusted.
  • For isotretinoin and SCC, HRs for the first quartile were as follows: HR = 2.38, 95% CI = 1.35-4.19 crude; HR = 1.69, 95% CI = 0.87-3.31 adjusted.
  • These analyses confirm the results of the original intent to treat analyses and raise an interesting question related to the potential for increased risk for patients in the first quartile of retinol dose.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin A.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • Hazardous Substances Data Bank. VITAMIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Control Clin Trials. 2000 Jun;21(3):241-3 [10822121.001]
  • [Cites] Br J Dermatol. 1999 Apr;140(4):656-60 [10233316.001]
  • [Cites] Nutrition. 2000 Nov-Dec;16(11-12):1084-9 [11118831.001]
  • [Cites] Australas J Dermatol. 2002 Nov;43(4):269-73 [12423433.001]
  • [Cites] J Am Acad Dermatol. 2003 Oct;49(4):644-50 [14512910.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1297-305 [15138569.001]
  • [Cites] Br J Cancer. 1970 Jun;24(2):235-52 [5451567.001]
  • [Cites] Agents Actions. 1970 Aug;1(4):172-5 [5520364.001]
  • [Cites] Nutr Rev. 1977 Apr;35(4):65-9 [854240.001]
  • [Cites] Biochim Biophys Acta. 1980 Mar 12;605(1):33-91 [6989400.001]
  • [Cites] J Natl Cancer Inst. 1981 Jan;66(1):7-16 [6935468.001]
  • [Cites] Gynecol Oncol. 1981 Oct;12(2 Pt 2):S331-40 [6946954.001]
  • [Cites] J Am Acad Dermatol. 1982 Apr;6(4 Pt 2 Suppl):815-23 [6950957.001]
  • [Cites] Nutr Cancer. 1983;5(2):96-106 [6359074.001]
  • [Cites] J Clin Oncol. 1983 Jun;1(6):394-9 [6668507.001]
  • [Cites] Neoplasma. 1984;31(5):615-8 [6594593.001]
  • [Cites] Br J Cancer. 1986 Dec;54(6):957-61 [3801291.001]
  • [Cites] J Natl Cancer Inst. 2004 Dec 1;96(23):1743-50 [15572756.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1596-607 [16030089.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):441-50 [16595780.001]
  • [Cites] Cancer Treat Rep. 1987 Apr;71(4):391-405 [3548957.001]
  • [Cites] Ann Intern Med. 1987 Oct;107(4):499-502 [3477106.001]
  • [Cites] Dermatologica. 1987;175 Suppl 1:138-44 [3480250.001]
  • [Cites] N Engl J Med. 1988 Jun 23;318(25):1633-7 [3287161.001]
  • [Cites] J Am Acad Dermatol. 1988 Jul;19(1 Pt 2):176-85 [3165982.001]
  • [Cites] J Am Acad Dermatol. 1989 Jul;21(1):144-5 [2745766.001]
  • [Cites] N Engl J Med. 1990 Sep 20;323(12):795-801 [2202902.001]
  • [Cites] Stat Med. 1991 Oct;10(10):1595-605 [1947515.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 4;84(5):328-32 [1738183.001]
  • [Cites] Nutr Cancer. 1992;18(3):237-44 [1296197.001]
  • [Cites] Clin Pharmacol Ther. 1995 Jan;57(1):6-15 [7828382.001]
  • [Cites] J Clin Epidemiol. 1994 Aug;47(8):829-36 [7730885.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1933-8 [7636533.001]
  • [Cites] Biometrics. 1996 Sep;52(3):1002-17 [8805765.001]
  • [Cites] Cancer Lett. 1997 Mar 19;114(1-2):203-5 [9103292.001]
  • [Cites] J Clin Pharmacol. 1997 Aug;37(8):667-72 [9378838.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):957-61 [9367070.001]
  • [Cites] J Eur Acad Dermatol Venereol. 1998 Jan;10(1):42-7 [9552756.001]
  • [Cites] Pharmacol Rev. 1998 Jun;50(2):315-33 [9647871.001]
  • [Cites] Carcinogenesis. 2000 Jul;21(7):1271-9 [10874003.001]
  • (PMID = 21058193.001).
  • [ISSN] 1532-7914
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA027502; United States / NCI NIH HHS / CA / CA-27502; United States / NCI NIH HHS / CA / CA-34256
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11103-57-4 / Vitamin A; EH28UP18IF / Isotretinoin
  • [Other-IDs] NLM/ NIHMS583867; NLM/ PMC4104190
  •  go-up   go-down


Advertisement
4. Bath-Hextall FJ, Perkins W, Bong J, Williams HC: Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev; 2007;(1):CD003412
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventions for basal cell carcinoma of the skin.
  • BACKGROUND: Basal cell carcinoma (BCC) is the commonest skin cancer.
  • The first line treatment is usually surgical excision, but numerous alternatives are available.
  • OBJECTIVES: To assess the effects of treatments for basal cell carcinoma.
  • SELECTION CRITERIA: Inclusion criteria were adults with one or more histologically proven, primary basal cell carcinoma.
  • The primary outcome measure was recurrence at three to five years, measured clinically.
  • One study found no significant difference for recurrence at 30 months when Moh's micrographic surgery was compared to surgery for high risk facial BCCs, (RR 0.64, 95%CI 0.16,2.64).
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateOf] Cochrane Database Syst Rev. 2003;(2):CD003412 [12804465.001]
  • (PMID = 17253489.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 63
  •  go-up   go-down


5. Stafanous S: Five-year cycle of basal cell carcinoma management re-audit. Orbit; 2009;28(4):264-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Five-year cycle of basal cell carcinoma management re-audit.
  • AIM: To complete a 5-year audit cycle for all malignant lid tumours treated by one consultant (Stafanous) and re-audit the first work done in 2000 and 2001/2002.
  • The main aim was to find out the recurrence rate and presence of new lesions in 5-years' follow-up and determine whether it is safe to discharge patients after histological clearance and satisfactory reconstruction outcome rather than 5 years' follow-up.
  • The collected data was: Site and type of lesions, type of surgery, recurrence rate and new lesions.
  • RESULTS: Out of 112 cases identified, 104 were Basal Cell Carcinoma (BCC), 4 Squamous Cell Carcinoma (SCC), 3 Sebaceous Gland Carcinoma (SGC) and 1 Malignant Melanoma (MM).
  • Only 1/112 had recurrence at the same site during the follow-up period and 5 had new lesions at different periorbital sites.
  • CONCLUSION: There was no evidence of significant recurrence to justify the 5-years' follow-up.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Outcome Assessment (Health Care)
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Medical Audit. Melanoma / surgery. Middle Aged. Mohs Surgery. Neoplasm Recurrence, Local. Postoperative Complications. Reconstructive Surgical Procedures. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19839887.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Aguayo-Leiva IR, Ríos-Buceta L, Jaén-Olasolo P: [Surgical vs nonsurgical treatment of basal cell carcinoma]. Actas Dermosifiliogr; 2010 Oct;101(8):683-92
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical vs nonsurgical treatment of basal cell carcinoma].
  • [Transliterated title] Tratamiento quirúrgico vs. no quirúrgico en el carcinoma basocelular.
  • Numerous therapeutic options are now available for the treatment of basal cell carcinoma.
  • We first describe the available therapeutic options, including certain innovative treatments.
  • We have divided them into 2 main groups-surgical and nonsurgical-and focus on the indications, advantages, and disadvantages of each one, as well as on the cure and recurrence rates.
  • Then, based on the evidence reviewed, we attempt to provide an outline of the therapeutic strategies recommended in basal cell carcinoma, and the approach to be used in specific situations.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Cryosurgery. Fluorouracil / therapeutic use. Follow-Up Studies. Hedgehog Proteins / antagonists & inhibitors. Humans. Interferons / therapeutic use. Laser Therapy. Mohs Surgery. Neoplasm Recurrence, Local. Photochemotherapy. Phytotherapy. Plant Preparations / therapeutic use. Risk Factors. Semecarpus. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Actas Dermosifiliogr. 2011 Oct;102(8):633-4 [21798484.001]
  • (PMID = 20965011.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Hedgehog Proteins; 0 / Plant Preparations; 0 / SHH protein, human; 9008-11-1 / Interferons; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Perez S, Lopez-Saura P, Bello-Rivero I: Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer; 2009;9:262
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study.
  • The aim of this work was to evaluate the effect of a formulation containing IFNs-alpha and -gamma in synergistic proportions on patients with recurrent, advanced basal cell (BCC) or squamous cell skin carcinomas (SCSC).
  • This is the first report of such treatment in patients with advance non-melanoma skin cancer.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Interferons / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Bayes Theorem. Drug Resistance, Neoplasm. Female. Humans. Male. Medical Oncology / methods. Middle Aged. Prospective Studies. Recurrence. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2726-34 [10537335.001]
  • [Cites] J Am Acad Dermatol. 2006 Jun;54(6):1033-8 [16713458.001]
  • [Cites] Science. 2000 Jun 30;288(5475):2357-60 [10875919.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2001 Jan;239(1):35-40 [11271459.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):119-34 [11900988.001]
  • [Cites] Br J Dermatol. 2002 Jun;146(6):933-7 [12072058.001]
  • [Cites] J Interferon Cytokine Res. 2002 Jun;22(6):719-28 [12162884.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1485-95 [12368221.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):558-61 [12459527.001]
  • [Cites] Acta Ophthalmol Scand. 2002 Dec;80(6):674-5 [12485296.001]
  • [Cites] Dermatol Surg. 2003 Oct;29(10):1027-34 [12974699.001]
  • [Cites] BMJ. 2003 Oct 4;327(7418):794-8 [14525881.001]
  • [Cites] Dermatol Surg. 2004 Jan;30(1):116-20 [14692941.001]
  • [Cites] Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):389-402 [15197337.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):342-6 [2405109.001]
  • [Cites] EMBO J. 1990 Apr;9(4):1105-11 [2108862.001]
  • [Cites] Int Ophthalmol. 1990 Jul;14(4):285-94 [2370130.001]
  • [Cites] Cancer Immunol Immunother. 1990;31(5):321-4 [2115817.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1637-49 [2120392.001]
  • [Cites] J Am Acad Dermatol. 1990 Oct;23(4 Pt 1):694-700 [2229497.001]
  • [Cites] Arch Dermatol. 1990 Dec;126(12):1660 [2256701.001]
  • [Cites] J Am Acad Dermatol. 1991 May;24(5 Pt 1):715-9 [1869642.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):235-41 [1734084.001]
  • [Cites] J Am Acad Dermatol. 1992 Jul;27(1):65-9 [1619079.001]
  • [Cites] Arch Dermatol. 1992 Nov;128(11):1486-9 [1444502.001]
  • [Cites] Ann Ophthalmol. 1993 Jan;25(1):11-3 [8427483.001]
  • [Cites] Drug Saf. 1994 Feb;10(2):115-50 [7516663.001]
  • [Cites] J Am Acad Dermatol. 1994 Nov;31(5 Pt 2):916-20 [7962748.001]
  • [Cites] Drugs. 1995 Jul;50(1):48-61 [7588089.001]
  • [Cites] Chin Med Sci J. 2007 Mar;22(1):38-43 [17441316.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1974-8 [17513803.001]
  • [Cites] Arch Dermatol. 2007 Jul;143(7):889-92 [17638733.001]
  • [Cites] J Immunother. 2008 Jan;31(1):28-33 [18157009.001]
  • [Cites] Acta Pol Pharm. 2008 May-Jun;65(3):345-51 [18646554.001]
  • [Cites] J Immunother. 2008 Sep;31(7):599-606 [18600184.001]
  • [Cites] Carcinogenesis. 2009 Feb;30(2):205-13 [18849299.001]
  • [Cites] Br J Nurs. 2009 Mar 26-Apr 8;18(6):346, 348-50 [19329898.001]
  • [Cites] Cancer Detect Prev. 1997;21(2):191-5 [9101080.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2691-6 [9389732.001]
  • [Cites] Dermatol Clin. 1998 Apr;16(2):377-98 [9589211.001]
  • [Cites] Acta Oncol. 1999;38(5):613-7 [10427950.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1849-57 [15547726.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 May;131(5):300-4 [15619125.001]
  • [Cites] Ophthalmology. 2005 Apr;112(4):717-23 [15808267.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2937-46 [15837745.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):24-37 [16397525.001]
  • [Cites] Mod Pathol. 2006 Feb;19 Suppl 2:S127-47 [16446711.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] J Immunol. 2000 Jan 1;164(1):217-22 [10605014.001]
  • (PMID = 19643007.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9008-11-1 / Interferons
  • [Other-IDs] NLM/ PMC2724551
  •  go-up   go-down


8. Rouet V, Bogorad RL, Kayser C, Kessal K, Genestie C, Bardier A, Grattan DR, Kelder B, Kopchick JJ, Kelly PA, Goffin V: Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. Proc Natl Acad Sci U S A; 2010 Aug 24;107(34):15199-204
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors.
  • Androgen-independent recurrence is the major limit of androgen ablation therapy for prostate cancer.
  • Stat5 has been recently shown to promote human prostate cancer cell survival/proliferation and to be associated with early prostate cancer recurrence.
  • The first aim of this study was to use prostate-specific PRL transgenic mice to address the mechanisms by which local PRL induces prostate tumorogenesis.
  • We report that (i) Stat5 is the major signaling cascade triggered by local PRL in the mouse dorsal prostate, (ii) this model recapitulates prostate tumorogenesis from precancer lesions to invasive carcinoma, and (iii) tumorogenesis involves dramatic accumulation and abnormal spreading of p63-positive basal cells, and of stem cell antigen-1-positive cells identified as a stem/progenitor-like subpopulation.
  • Because basal epithelial stem cells are proposed to serve as tumor-initiating cells, we challenged the relevance of local PRL as a previously unexplored therapeutic target.
  • Using a double-transgenic approach, we show that Delta1-9-G129R-hPRL, a competitive PRL-receptor antagonist, prevented early stages of prostate tumorogenesis by reducing or inhibiting Stat5 activation, cell proliferation, abnormal basal-cell pattern, and frequency or grade of intraepithelial neoplasia.
  • This study identifies PRL receptor/Stat5 as a unique pathway, initiating prostate tumorogenesis by altering basal-/stem-like cell subpopulations, and strongly supports the importance of further developing strategies to target locally overexpressed PRL in human prostate cancer.
  • [MeSH-minor] Animals. Base Sequence. Cell Proliferation. DNA Primers / genetics. Humans. Male. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Mice, Inbred CBA. Mice, Transgenic. Neoplastic Stem Cells / metabolism. Neoplastic Stem Cells / pathology. Peptide Fragments / genetics. Peptide Fragments / metabolism. Prostate / metabolism. Prostate / pathology. Rats. Receptors, Prolactin / antagonists & inhibitors. Recombinant Proteins / genetics. Recombinant Proteins / metabolism. STAT5 Transcription Factor / metabolism. Signal Transduction. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 2003 Jul;144(7):3196-205 [12810576.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):35988-99 [12824168.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7841-6 [12799464.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):209-21 [14522255.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4955-66 [12960074.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2270-305 [15026373.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4774-82 [15256446.001]
  • [Cites] J Clin Invest. 1997 Feb 15;99(4):618-27 [9045863.001]
  • [Cites] Endocr Rev. 1998 Jun;19(3):225-68 [9626554.001]
  • [Cites] Clin Sci (Lond). 2005 Jan;108(1):1-11 [15384949.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 10;102(19):6942-7 [15860580.001]
  • [Cites] Endocr Rev. 2005 May;26(3):400-22 [15814850.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 17;102(20):7180-5 [15899981.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5863-8 [16115927.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1480-5 [16432235.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):989-1008 [17138649.001]
  • [Cites] Endocrinology. 2007 Jul;148(7):3089-101 [17412813.001]
  • [Cites] J Clin Invest. 2007 Aug;117(8):2044-50 [17671638.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1317-24 [18316550.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2862-70 [18539965.001]
  • [Cites] J Clin Invest. 2008 Sep;118(9):3051-64 [18725989.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14533-8 [18779591.001]
  • [Cites] Urology. 2009 May;73(5 Suppl):S4-10 [19375626.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2610-5 [20133806.001]
  • [Cites] Endocrinology. 2003 Jun;144(6):2269-78 [12746285.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):727-35 [12163397.001]
  • [Cites] Toxicol Pathol. 2002 Mar-Apr;30(2):228-34 [11950166.001]
  • [Cites] Endocrinology. 2002 Jan;143(1):228-38 [11751614.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1769-75 [11106548.001]
  • [CommentIn] Nat Rev Urol. 2010 Nov;7(11):591 [21113991.001]
  • (PMID = 20699217.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Grant] United Kingdom / Worldwide Cancer Research / / 05-0603
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Peptide Fragments; 0 / Receptors, Prolactin; 0 / Recombinant Proteins; 0 / STAT5 Transcription Factor; 9002-62-4 / Prolactin
  • [Other-IDs] NLM/ PMC2930529
  •  go-up   go-down


9. Ramachandran S, Rajaratnam R, Smith AG, Lear JT, Strange RC: Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma. J Am Acad Dermatol; 2009 Aug;61(2):247-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma.
  • BACKGROUND: The rate of development of further basal cell carcinoma (BCC) after first presentation is highly variable.
  • OBJECTIVE: We assessed the risks of developing a subsequent BCC in patients who developed a BCC and a squamous cell carcinoma (SCC) and compared them with patients who developed a BCC only.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neoplasms, Multiple Primary / epidemiology
  • [MeSH-minor] Age Distribution. Aged. Aged, 80 and over. Cohort Studies. Confidence Intervals. Female. Humans. Immunohistochemistry. Incidence. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Probability. Prognosis. Risk Assessment. Sex Distribution

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19481292.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Chadha V, Wright M: Small margin excision of periocular basal cell carcinomas. Br J Ophthalmol; 2009 Jun;93(6):803-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small margin excision of periocular basal cell carcinomas.
  • AIMS: To analyse the outcome of small margin (up to 2 mm) excision of primary clinically well-defined periocular basal cell carcinomas (BCCs).
  • Histological assessment confirmed complete excision after the first excision in 78 (86.7%) rising to 83 (92.2%) after two excisions.
  • Overall the recurrence rate in our study was 3.3% (n = 3).
  • CONCLUSIONS: Our recurrence rate compares well with published results following conventional excision of BCCs.
  • In the absence of availability of Mohs surgery, well-demarcated nodular basal cell carcinomas can be safely excised using smaller margins than conventionally practised.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Ophthalmol. 2010 Aug;94(8):1114 [20530178.001]
  • (PMID = 19304655.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Wisgerhof HC, Edelbroek JR, de Fijter JW, Haasnoot GW, Claas FH, Willemze R, Bavinck JN: Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation; 2010 May 27;89(10):1231-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors.
  • The aim of this study was to estimate the cumulative incidence of subsequent squamous- and basal-cell carcinomas (BCCs) and to analyze potential risk factors.
  • The cumulative incidence of a second skin cancer increased from 32%, 1 year, to 59%, 3 years, and 72%, 5 years after the first skin cancer.
  • KTR who started with squamous-cell carcinoma (SCC) mainly developed SCC and recipients who started with BCC mainly developed BCC as second skin cancer.
  • Patients with a first skin cancer are at increased risk for more skin cancers and need to be carefully checked for subsequent skin cancers.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Kidney Transplantation / adverse effects. Skin Neoplasms / epidemiology
  • [MeSH-minor] Azathioprine / adverse effects. Azathioprine / therapeutic use. Female. Humans. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Incidence. Male. Neoplasm Recurrence, Local / epidemiology. Prednisone / adverse effects. Prednisone / therapeutic use. Proportional Hazards Models. Retrospective Studies. Risk Factors. Sunlight / adverse effects. Time Factors

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20410852.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; MRK240IY2L / Azathioprine; VB0R961HZT / Prednisone
  •  go-up   go-down


12. Farhadi M, Kamrava SK, Behzadi AH, Rafiezadeh P, Asghari A, Rezvan F, Maleki S: The efficacy of photodynamic therapy in treatment of recurrent squamous cell and basal cell carcinoma. J Drugs Dermatol; 2010 Feb;9(2):122-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of photodynamic therapy in treatment of recurrent squamous cell and basal cell carcinoma.
  • OBJECTIVES: A number of investigations have already been carried out to assess the effect of photodynamic therapy (PDT) on primary basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) lesions, but lack of investigations on recurrent lesions or lesions with treatment failure, prompted the authors to carry out this study.
  • RESULTS: To cite the results obtained in this study, it is worth mention that five cases expressed disagreement with this treatment modality after the first session of illumination; the treatment was stopped because of pain or burning.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy


13. Gollnick H, Barona CG, Frank RG, Ruzicka T, Megahed M, Maus J, Munzel U: Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol; 2008 Nov-Dec;18(6):677-82
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe.
  • Imiquimod 5% cream is an immune response modifier approved for the treatment of superficial basal cell carcinoma (sBCC) once daily, 5 x per week for 6 weeks.
  • This report reveals the final results of a 5-year follow-up study to evaluate the recurrence rate of sBCCs treated with imiquimod.
  • During the follow-up period, 18 clinical recurrences occurred at the target tumour site, 8 and 10 of which occurred during the first 6 and 12 months of follow-up, respectively.
  • Most of the recurrences occurred early, indicating that careful follow-up is important during the first year after treatment.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Neoplasm Recurrence, Local. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955210.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


14. Busam KJ, Halpern A, Marghoob AA: Malignant melanoma metastatic to a basal cell carcinoma simulating the pattern of a basomelanocytic tumor. Am J Surg Pathol; 2006 Jan;30(1):133-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma metastatic to a basal cell carcinoma simulating the pattern of a basomelanocytic tumor.
  • We report a case of metastatic melanoma colliding with and colonizing a basal cell carcinoma (BCC) on the head of a 69-year-old man.
  • The intimate association of melanoma cells within the nodules of BCC simulated the pattern of so-called "malignant basomelanocytic tumor," a recently proposed novel entity.
  • To our knowledge, this is the first description of metastatic melanoma colonizing a BCC.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Neoplasm Recurrence, Local / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330954.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Kuijpers DI, Thissen MR, Berretty PJ, Ideler FH, Nelemans PJ, Neumann MH: Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatol Surg; 2007 May;33(5):579-87
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma.
  • BACKGROUND: Both cryosurgery, with and without prior curettage, and surgical excision (SE) are common therapeutic strategies for basal cell carcinoma (BCC).
  • The overall 5-year recurrence probability was 19.6% for C&C and 8.4% for SE (p=.10).
  • CONCLUSION: These data reflect the outcome of the first randomized controlled trial with long-term follow-up in the treatment of BCC, comparing C&C with SE.
  • Owing to the trend toward lower recurrence rates, better cosmetic results, and reduced wound healing time, we believe that SE should be preferred to C&C in the treatment of primary, nonaggressive BCC of the head and neck.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2008 Apr;34(4):582 [18248484.001]
  • (PMID = 17451581.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


16. Griffiths RW, Suvarna SK, Stone J: Do basal cell carcinomas recur after complete conventional surgical excision? Br J Plast Surg; 2005 Sep;58(6):795-805
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do basal cell carcinomas recur after complete conventional surgical excision?
  • For 1378 patients treated in the 11 years 1988-1998 by conventional excision of 1635 basal cell carcinomas, 1516 first index lesions were histologically completely excised.
  • The median interval to recurrence was 41 months (4 months-8 years 10 months), with median lateral clearance margin around the primary tumour of 2 mm (0.3-6.8 mm).
  • The median interval to recurrence was 59 months (1 year-8 years 6 months).
  • For the two groups combined the maximum recurrence rate expressed as a percentage of index lesions was 1.3% (20/1516).
  • These figures indicate there is a low order of probability for the incidence of recurrent basal cell carcinoma during minimum 5 years follow period after conventional surgical excision and conventional histological assessment of tumour resection margins.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Plast Reconstr Aesthet Surg. 2007;60(4):451-3 [17349608.001]
  • [CommentIn] J Plast Reconstr Aesthet Surg. 2006;59(11):1247 [17046636.001]
  • (PMID = 16086990.001).
  • [ISSN] 0007-1226
  • [Journal-full-title] British journal of plastic surgery
  • [ISO-abbreviation] Br J Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Garcia L, Nagore E, Llombart B, Sanmartin O, Botella-Estrada R, Requena C, Jorda E, Guillen C: Basal cell carcinoma of the nasolabial fold: an apparently 'benign' tumour that often needs complex surgery. J Eur Acad Dermatol Venereol; 2006 Sep;20(8):926-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the nasolabial fold: an apparently 'benign' tumour that often needs complex surgery.
  • BACKGROUND: Location of the tumour is a well-known prognostic factor for recurrence of basal cell carcinoma (BCC).
  • RESULTS: BCC on the nasolabial fold presented with shorter evolution time from first symptom, had a smaller size, had been less frequently treated before and showed mostly non-aggressive histologic subtype, but needed more surgical stages and more complex reconstruction.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16922939.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


18. Calista D: Photodynamic therapy for the treatment of a giant superficial basal cell carcinoma. Photodermatol Photoimmunol Photomed; 2009 Feb;25(1):53-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for the treatment of a giant superficial basal cell carcinoma.
  • A 74-year-old man was referred to our department for the treatment of a 15 x 15 cm superficial basal cell carcinoma (BCC) on his lumbar region.
  • No recurrence has occurred after a 40-month follow-up period, but clinical observation continues.
  • As far as we know, this is the first case of giant BCC treated with PDT.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / radiotherapy. Photochemotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19152518.001).
  • [ISSN] 1600-0781
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


19. Lovatt TJ, Lear JT, Bastrilles J, Wong C, Griffiths CE, Samarasinghe V, Roebuck J, Ramachandran S, Smith AG, Jones PW, Fryer AA, Strange RC: Associations between ultraviolet radiation, basal cell carcinoma site and histology, host characteristics, and rate of development of further tumors. J Am Acad Dermatol; 2005 Mar;52(3 Pt 1):468-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Associations between ultraviolet radiation, basal cell carcinoma site and histology, host characteristics, and rate of development of further tumors.
  • BACKGROUND: Patients with basal cell carcinoma (BCC) frequently develop further tumors during follow-up.
  • OBJECTIVE: We sought to elucidate the relative effects of pattern of ultraviolet radiation exposure, and site and histologic type of the first tumor, on the rate of increase in BCC numbers.
  • METHODS: We used negative binomial regression analysis to study the association of selected variables on the rate of increase in BCC numbers in 266 Caucasian patients who first presented with a tumor on the head/neck or trunk with nodular or superficial histology.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761425.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Mc Loone NM, Tolland J, Walsh M, Dolan OM: Follow-up of basal cell carcinomas: an audit of current practice. J Eur Acad Dermatol Venereol; 2006 Jul;20(6):698-701
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follow-up of basal cell carcinomas: an audit of current practice.
  • BACKGROUND: Follow-up of patients after treatment of basal cell carcinoma (BCC) allows for monitoring of recurrence and detection of new tumours, but adds a significant burden to outpatient clinics.
  • OBJECTIVES: An audit was undertaken to determine the quality of data set recorded relating to prognostic factors for BCCs to determine the rate of recurrence and number of new primary tumours detected and to determine the completeness of follow-up by patients.
  • The rate of recurrence was low, with 2 BCC recurring within 2 years of excision.
  • The risk of developing a new BCC was 11.6% in the first year and 6.3% in the second year.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Guideline Adherence. Practice Guidelines as Topic. Skin Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Incidence. Male. Medical Audit. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / epidemiology. Practice Patterns, Physicians' / statistics & numerical data. Prognosis. Risk Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16836498.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


21. Mertz KD, Proske D, Kettelhack N, Kegel C, Keusch G, Schwarz A, Ambühl PM, Pfaltz M, Kempf W: Basal cell carcinoma in a series of renal transplant recipients: epidemiology and clinicopathologic features. Int J Dermatol; 2010 Apr;49(4):385-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma in a series of renal transplant recipients: epidemiology and clinicopathologic features.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common malignancy among Caucasians worldwide.
  • OBJECTIVE: To analyze the incidence, clinical presentation, histologic features, treatment and recurrence rate of BCC in a cohort of 69 renal transplant recipients (RTRs; 53 male).
  • Mean age at first diagnosis of BCC was 65.5 +/- 8.5 years, and latency between kidney transplantation and diagnosis of the first BCC was 11.1 +/- 6.3 years (mean +/- SD).
  • Recurrence after surgical excision was observed in one of the 10 patients (10%).
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Immunocompromised Host. Kidney Transplantation. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Sex Factors. Young Adult

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20465691.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Pandeya N, Purdie DM, Green A, Williams G: Repeated occurrence of basal cell carcinoma of the skin and multifailure survival analysis: follow-up data from the Nambour Skin Cancer Prevention Trial. Am J Epidemiol; 2005 Apr 15;161(8):748-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated occurrence of basal cell carcinoma of the skin and multifailure survival analysis: follow-up data from the Nambour Skin Cancer Prevention Trial.
  • The aim of this study was to apply multifailure survival methods to analyze time to multiple occurrences of basal cell carcinoma (BCC).
  • Data from 4.5 years of follow-up in a randomized controlled trial, the Nambour Skin Cancer Prevention Trial (1992-1996), to evaluate skin cancer prevention were used to assess the influence of sunscreen application on the time to first BCC and the time to subsequent BCCs.
  • Sunscreen treatment was not associated with time to first occurrence of a BCC (hazard ratio = 1.04, 95% confidence interval: 0.79, 1.45).
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Neoplasm Recurrence, Local / epidemiology. Skin Neoplasms / epidemiology. Sunscreening Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800267.001).
  • [ISSN] 0002-9262
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sunscreening Agents
  •  go-up   go-down


23. Hassanpour SE, Kalantar-Hormozi A, Motamed S, Moosavizadeh SM, Shahverdiani R: Basal cell carcinoma of scalp in patients with history of childhood therapeutic radiation: a retrospective study and comparison to nonirradiated patients. Ann Plast Surg; 2006 Nov;57(5):509-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of scalp in patients with history of childhood therapeutic radiation: a retrospective study and comparison to nonirradiated patients.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common human malignant neoplasm.
  • We compared these 2 groups in 16 different parameters, which included general information (age, sex), disease history (time interval from onset of lesion to the first office visit, number of admissions, total length of hospital stay), tumor specifications (number of primary lesions, invasion depth, histologic subtypes, location), surgical history (number of operations in our center and other hospitals, type of surgical treatment, margins of resection), recurrences, new lesions, and metastasis.
  • There was no meaningful difference in safe resection margin for the first lesion between the 2 groups (P = 0.27); however, the number of recurrent lesions was significantly higher in group A (P = 0.003).
  • Also, these patients should be under close observation because there is a higher chance for tumor recurrence and also new lesions occurring elsewhere in the scalp.
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Basal Cell / surgery. Reconstructive Surgical Procedures / methods. Skin Neoplasms / radiotherapy. Skin Neoplasms / surgery. Survivors / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Plast Surg. 2007 May;58(5):589; author reply 589-90 [17452854.001]
  • (PMID = 17060730.001).
  • [ISSN] 0148-7043
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Cada Z, Chovanec M, Smetana K, Betka J, Lacina L, Plzák J, Kodet R, Stork J, Lensch M, Kaltner H, André S, Gabius HJ: Galectin-7: will the lectin's activity establish clinical correlations in head and neck squamous cell and basal cell carcinomas? Histol Histopathol; 2009 01;24(1):41-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-7: will the lectin's activity establish clinical correlations in head and neck squamous cell and basal cell carcinomas?
  • The human lectin galectin-7 (Gal-7; p53-induced gene-1) has anti- and pro-malignant features in different in vitro models.
  • We tried to clarify relation of its expression to cellular and clinical parameters in head and neck squamous and basal cell carcinomas.
  • Using a non-cross-reactive antibody, immunohistochemical staining in squamous cell epithelia (epidermis, epithelium of oropharynx and larynx) (n = 57), squamous cell carcinomas (n = 47) and lymph node metastases (n = 25), as well as basal cell carcinomas (n = 10) were studied.
  • This monitoring was flanked by processing to assess the level of differentiation (cytokeratins 10 and 14), proliferation (Ki67) and basal lamina formation (collagen IV).
  • The results were correlated with clinical and pathological findings (grading, TNM-staging, extracapsular spread, angio- and lymphangioinvasion, perineural invasion, recurrence and survival).
  • Basal cell carcinomas were devoid of the Gal-7 respective signal.
  • Squamous cell carcinomas were positive, presenting different staining profiles.
  • Intense staining was predominantly found in squamous cell cancers with high degrees of differentiation and keratinization.
  • Fittingly, poor level of differentiation (P = 0.0009), absence of keratinization (P = 0.0105) and significant discontinuity or absence of collagen IV expression in the peritumoral basal lamina (P = 0.0024) was found in Gal-7-negative tumors.
  • Immunohistochemical analysis revealed a positive correlation for differentiation and keratinization to Gal-7 presence in squamous cell carcinomas.
  • Absence of Gal-7 expression was detected in basal cell carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Galectins / metabolism. Head and Neck Neoplasms / metabolism
  • [MeSH-minor] Cell Differentiation. Collagen Type IV / biosynthesis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Keratin-14 / biosynthesis. Ki-67 Antigen / biosynthesis. Male. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19012243.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Collagen Type IV; 0 / Galectins; 0 / Keratin-14; 0 / Ki-67 Antigen; 0 / LGALS7 protein, human
  •  go-up   go-down


25. Walker P, Hill D: Surgical treatment of basal cell carcinomas using standard postoperative histological assessment. Australas J Dermatol; 2006 Feb;47(1):1-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of basal cell carcinomas using standard postoperative histological assessment.
  • SUMMARY Surgical treatment of basal cell carcinomas using postoperative histological assessment is routinely practised in Australia.
  • The first is case selection that requires an understanding of the limitations of the procedure.
  • Tumour recurrence is rare (less than 2% at 5 years) if the tumour is clear of the surgical margin.
  • Tumour recurrence averages 38% when the histological margin is involved.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Mohs Surgery / methods. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Biopsy, Needle. Education, Medical, Continuing. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Reoperation. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405477.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 95
  •  go-up   go-down


26. Lawrence CM, Haniffa M, Dahl MG: Formalin-fixed tissue Mohs surgery (slow Mohs) for basal cell carcinoma: 5-year follow-up data. Br J Dermatol; 2009 Mar;160(3):573-80
Hazardous Substances Data Bank. FORMALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Formalin-fixed tissue Mohs surgery (slow Mohs) for basal cell carcinoma: 5-year follow-up data.
  • BACKGROUND: Mohs surgery using a formalin-fixed tissue technique (slow Mohs) was used to treat 1090 basal cell carcinomas (BCCs) occurring in 1000 patients without Gorlin syndrome in a prospective, open nonrandomized trial of therapy carried out in a university dermatology department.
  • The mean interval between the first Mohs excision and Mohs clearance, regardless of the closure technique, was 4.2 days (range 0-44) and the mean interval between tumour clearance and defect closure was 1.9 days (range 0-49).
  • The mean tumour recurrence time was 2.5 years (range 0.6-4.99) following Mohs excision.
  • There was a higher risk of recurrence for big (four of 78; 5%) and recurrent (nine of 193; 5%) BCCs compared with other indications for Mohs surgery.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Mohs Surgery / methods. Skin Neoplasms / surgery. Tissue Fixation / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Follow-Up Studies. Formaldehyde. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Pathology, Surgical / methods. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19210500.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 1HG84L3525 / Formaldehyde
  •  go-up   go-down


27. Allen SB, Lortscher DN, Sengelmann RD: Earlier detection of patients' second primary basal cell carcinomas: a quantitative analysis. Dermatol Surg; 2007 Jan;33(1):69-72
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Earlier detection of patients' second primary basal cell carcinomas: a quantitative analysis.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common occurring cancer in humans.
  • No studies to date have compared the size of a patient's first and second primary BCC to determine whether we are detecting and treating second primary cancers at earlier stages of development.
  • We compared the presenting clinical size of patients' first and second primary BCC.
  • RESULTS: We found a statistically significant decrease in size of the second primary BCC when compared to the first primary BCC (p<.0001).
  • Earlier detection of skin cancers can decrease the morbidity and chance of recurrence as well as lead to smaller scars and better cosmetic outcomes and may also allow for various treatment modalities and cost containment.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Neoplasms, Second Primary / pathology. Skin Neoplasms / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Early Diagnosis. Female. Follow-Up Studies. Humans. Male. Middle Aged. Mohs Surgery. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214681.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Liu H, Fan QH, Zhang ZH, Li X, Yu HP, Liu GZ, Meng FQ: [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer]. Zhonghua Bing Li Xue Za Zhi; 2009 Jan;38(1):23-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
  • OBJECTIVES: Basal cell-like breast cancer is one of the subtypes using molecular typing, and this subtype attracted a wide spread attention.
  • The prognosis of basal cell-like breast cancer using different immunohistochemical criteria were analyzed.
  • Based on the results, these cases using four different diagnostic criteria were categorized, namely: Nielsen (ER-/HER2-, CK5/6+ and/or EGFR+), Kim (ER-/PR-/HER2-, CK5/6+ and/or CK14+ and/or EGFR+), Triple-negative (ER-/PR-/HER2-), and basal-CK (CK5/6+ and/or CK14+).
  • RESULTS: The prevalence of basal cell-like breast cancer by Nielsen, Kim, Triple-negative and basal-CK were 15.5% (44/284), 14.8% (42/284), 43.3% (123/284) and 21.1% (60/284) respectively; the recurrence rates were 18.2% (8/44), 21.4% (9/42), 10.6% (13/123) and 11.7% (7/60) respectively.
  • These were higher than recurrence rates for other subtypes, but only the differences by Nielsen's and Kim's criteria were significant.
  • Using Nielsen's and Triple-negative's criteria, basal-like tumors showed shorter 5-year disease-free survival (both P < 0.
  • 01) and overall survival (P < 0.05 and 0.01) than luminal A subtype, using Kim's criteria, basal-like tumors showed a lower 5-year disease-free but not overall survival than luminal A subtype (P < 0.01); no significant difference was found on 5-year survival between basal-like and non-basal-like tumors when typed by basal-CK.
  • CONCLUSION: Basal cell-like breast cancers are more likely to show more recurrence and worse outcome, but different immunohistochemical diagnostic criteria have an influence on their prognostic analysis, so a uniform diagnostic criteria is essential for the further study of basal-like breast cancers.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Neoplasms, Basal Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Keratin-5 / metabolism. Keratin-6 / metabolism. Lung Neoplasms / secondary. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19489221.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Keratin-5; 0 / Keratin-6; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


29. Quirk C, Gebauer K, De'Ambrosis B, Slade HB, Meng TC: Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis; 2010 Jun;85(6):318-24
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study.
  • We conducted a prospective, multicenter, phase 3, open-label study to assess long-term sustained clearance of superficial basal cell carcinomas (sBCCs) treated with imiquimod cream 5%.
  • Tumor recurrence, serious adverse events (AEs), local skin reactions (LSRs), and skin quality assessments (SQAs) were measured.
  • Of 20 recurrent tumors, 74 (70%) occurred within the first 24 months of follow-up.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Follow-Up Studies. Humans. Neoplasm Recurrence, Local. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666194.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


30. Tillman DK Jr, Carroll MT: A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. J Drugs Dermatol; 2008 Jan;7(1 Suppl 1):s7-14
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma.
  • BACKGROUND: Electrodesiccation and curettage is commonly used for the treatment of basal cell carcinomas (BCCs).
  • METHODS: Patients were enrolled into the study in the first 10 months of 2003.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / therapy. Curettage. Skin Neoplasms / therapy
  • [MeSH-minor] Administration, Cutaneous. Adult. Aged. Aged, 80 and over. Biopsy. Combined Modality Therapy. Electrosurgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prospective Studies

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277457.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


31. Bradford C, Wack A, Trembley S, Southard T, Bronson E: Two cases of neoplasia of basal cell origin affecting the axillary region in anseriform species. J Avian Med Surg; 2009 Sep;23(3):214-21
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of neoplasia of basal cell origin affecting the axillary region in anseriform species.
  • This mass was diagnosed as a basosquamous carcinoma.
  • The mass was surgically excised, and no recurrence was observed.
  • Basosquamous carcinoma may have a similar gross appearance.
  • This appears to be the first report of feather folliculoma and basosquamous carcinoma in Anseriforme species.
  • Feather folliculomas and other neoplasms, such as basosquamous carcinoma, should be considered as a differential diagnosis in ulcerative or proliferative skin lesions in birds.
  • [MeSH-major] Bird Diseases / pathology. Ducks. Neoplasms, Basal Cell / veterinary. Skin Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999766.001).
  • [ISSN] 1082-6742
  • [Journal-full-title] Journal of avian medicine and surgery
  • [ISO-abbreviation] J. Avian Med. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Hernández-Machin B, Borrego L, Gil-García M, Hernández BH: Office-based radiation therapy for cutaneous carcinoma: evaluation of 710 treatments. Int J Dermatol; 2007 May;46(5):453-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Office-based radiation therapy for cutaneous carcinoma: evaluation of 710 treatments.
  • The authors sought to evaluate the effectiveness and safety of office-based elective radiation therapy for cutaneous carcinoma.
  • A retrospective study of 604 basal cell carcinomas (BCCs) and 106 squamous cell carcinomas (SCCs) irradiated between 1971-96 was performed.
  • The percentage of patients who developed tumor recurrence during the follow-up period was calculated using Kaplan-Meier survival curves.
  • The recurrence rates for BCC and SCC were 11.5 and 16.5 per 1000 patient-years, respectively.
  • Tumor location on the nasolabial fold (OR 4.4; 95% IC, 1.3-14.7) and tumor size > or = 10 mm (OR 2.14; 95% IC, 1.03-4.45) were independent predictors of BCC recurrence.
  • This study suggested that radiation therapy is an effective treatment for BCC and SCC and should be considered as a first option in many cases.
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Radiation Dosage. Radiotherapy / methods. Radiotherapy / statistics & numerical data. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472670.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Suciu V, Botan E, Valent A, Chami L, Spatz A, Vielh P: The potential contribution of fluorescent in situ hybridization analysis to the cytopathological diagnosis of Merkel cell carcinoma. Cytopathology; 2008 Feb;19(1):48-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential contribution of fluorescent in situ hybridization analysis to the cytopathological diagnosis of Merkel cell carcinoma.
  • We report the cases of two patients with head and neck Merkel cell carcinoma (MCC) who developed local recurrences confirmed by cytopathology.
  • Trisomy of chromosome 6 was found in 85% of tumour cells in the first case of MCC and case 2 exhibited trisomy 8 in 77% of tumour cells.
  • [MeSH-major] Carcinoma, Merkel Cell / genetics. In Situ Hybridization, Fluorescence. Neoplasm Recurrence, Local / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Fine-Needle. Breast Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Chromosomes, Human, Pair 6 / genetics. Chromosomes, Human, Pair 8 / genetics. Female. Humans. Immunohistochemistry. Male. Neoplasms, Second Primary / genetics. Neoplasms, Second Primary / pathology. Trisomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18205628.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


34. Ogunsalu C, Daisley H, Kamta A, Kanhai D, Mankee M, Maharaj A: Odontogenic keratocyst in Jamaica: a review of five new cases and five instances of recurrence together with comparative analyses of four treatment modalities. West Indian Med J; 2007 Jan;56(1):90-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Odontogenic keratocyst in Jamaica: a review of five new cases and five instances of recurrence together with comparative analyses of four treatment modalities.
  • AIM: Five new cases of odontogenic keratocyst (OKC) together with five instances of recurrence are reviewed with special emphasis on radiology and surgical management.
  • Cases of recurrence were separated from new cases.
  • RESULTS: Five new cases and five instances of recurrence were documented over the 25-year period The new cases of OKC keratocyst accounted for 1.71% of the total jaw bone tumours and 12% of OKC keratocysts over the first 16 years.
  • Of significance, one case of nevoid basal cell carcinoma syndrome (NBCCS) and a case of ameloblastomatous transformation in the wall of an OKC keratocyst were recorded The age range of the new cases was 12 to 44 years.
  • A case of OKC in NBCCS is also documented Of all four surgical treatment modalities compared, only cryosurgery was promising, so far with no recurrence after a follow-up period of six years.
  • [MeSH-minor] Adult. Cryosurgery. Female. Humans. Jamaica. Male. Radiography, Panoramic. Recurrence. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621852.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Jamaica
  •  go-up   go-down


35. Fischer S, Breuninger H, Metzler G, Hoffmann J: Microcystic adnexal carcinoma: an often misdiagnosed, locally aggressive growing skin tumor. J Craniofac Surg; 2005 Jan;16(1):53-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adnexal carcinoma: an often misdiagnosed, locally aggressive growing skin tumor.
  • Microcystic adnexal carcinoma (MAC) belongs to the spectrum of locally aggressive adnexal carcinomas and most commonly occurs in the head and neck region.
  • In 1982, Goldstein and colleagues first reported MAC to be a distinct histologic entity characterized by a combination of keratinous cysts in the upper dermis, islands and strands of small basaloid, benign-appearing keratinocytes or squamous cells in the deeper dermis within a dense desmoplastic stroma, and areas of ductular differentiation.
  • The authors report the case of a 78-year-old woman in whom a diagnosis of MAC was made when a tumor on the right cheek recurred for the second time.
  • Previous histopathologic diagnoses were squamous cell carcinoma and desmoplastic trichoepithelioma.
  • The reported case demonstrates the difficulties in diagnosing MAC and indicates that MAC should always be considered in the differential diagnosis of slowly growing tumors in the head and neck region.
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Facial Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasms, Basal Cell / pathology

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15699645.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Hart AM, Tollan CJ, Dabernig J, Acland R, Taggart I: Tertiary resurfacing after one of the first free flaps in Europe, a reflection on 30 years of microsurgical progress. J Plast Reconstr Aesthet Surg; 2007;60(11):1263-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tertiary resurfacing after one of the first free flaps in Europe, a reflection on 30 years of microsurgical progress.
  • This case highlights the evolution from one of Europe's first free tissue transfers, effectively a perforator flap, through the advent of free muscle flaps to the current generation of contourable perforator flaps.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Head and Neck Neoplasms / surgery. Microsurgery / methods. Scalp / surgery. Skin Neoplasms / surgery. Surgical Flaps / blood supply
  • [MeSH-minor] Adolescent. Adult. Humans. Male. Neoplasm Recurrence, Local. Reconstructive Surgical Procedures / methods. Reconstructive Surgical Procedures / standards. Reoperation / methods. Reoperation / standards. Treatment Outcome. Ultrasonography, Doppler, Color

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17720645.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


37. Heitland W: [Diagnosis and therapy for anal carcinoma]. Chirurg; 2008 Feb;79(2):183-91; quiz 192
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapy for anal carcinoma].
  • Of all carcinomas in the anal canal, 75-80% are squamous cell carcinomas-the remaining 25% being adenocarcinomas.
  • Carcinomas of the anal margin are to be differentiated from basal cell carcinomas and Paget's and Bowen's diseases.
  • Primary radiochemotherapy is the first treatment option for epidermoid carcinomas of the anal canal and anal margin.
  • Surgery is reserved for the primary biopsy or excision of small tumors and for salvage abdominoperineal resection in patients with tumor persistence or local recurrence after radiochemotherapy.
  • The first follow-up examination should be done 6 weeks after the end of radiochemotherapy.
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Combined Modality Therapy. Humans. Lymph Node Excision. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Prognosis. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1984 Aug 1;54(3):411-5 [6329504.001]
  • [Cites] J Gastrointest Surg. 2001 Jul-Aug;5(4):383-7 [11985979.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):45-51 [12504657.001]
  • [Cites] Dis Colon Rectum. 2005 Jan;48(1):16-22 [15690652.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Dis Colon Rectum. 2004 Jul;47(7):1136-44 [15164245.001]
  • [Cites] World J Surg. 2005 Nov;29(11):1452-7 [16222445.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2062-8 [6435851.001]
  • [Cites] Colorectal Dis. 2006 Feb;8(2):124-9 [16412072.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479-85 [15890590.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):478-83 [17103253.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Am J Surg. 1985 Jan;149(1):95-101 [3966647.001]
  • [Cites] Ann Surg. 1976 Oct;184(4):422-8 [189707.001]
  • [Cites] Ann Surg. 1994 Jul;220(1):40-9 [8024357.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • (PMID = 18227955.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


38. Dore DD, Lapane KL, Trivedi AN, Mor V, Weinstock MA: Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial. Ann Intern Med; 2009 Jan 6;150(1):9-18
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial.
  • OBJECTIVE: To quantify the association between statin use and the occurrence of keratinocyte carcinoma in high-risk veterans.
  • PARTICIPANTS: 1037 participants of the Veterans Affairs Topical Tretinoin Chemoprevention Trial, a randomized, multicenter, double-blind, vehicle-controlled trial of topical tretinoin, 0.1%, for prevention of keratinocyte carcinoma conducted from November 1998 to November 2004.
  • MEASUREMENTS: Time to first occurrence of keratinocyte carcinoma on the face or ears.
  • In the propensity score-matched analysis, statin use at randomization was not associated with keratinocyte carcinoma (rate ratio, 0.92 [95% CI, 0.73 to 1.16]), a finding that was consistent with the estimates derived from the Cox proportional hazards regression (rate ratio, 0.84 [CI, 0.70 to 1.02]).
  • CONCLUSION: These data show no conclusive or consistent relationship between long-term statin use and risk for keratinocyte carcinoma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2006 Jun 21;295(23):2721; author reply 2721-2 [16788124.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):549-59 [16899775.001]
  • [Cites] Int J Clin Pract. 2006 Sep;60(9):1028-34 [16939542.001]
  • [Cites] Am J Cardiol. 2006 Oct 1;98(7):923-8 [16996875.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25 [17179483.001]
  • [Cites] Circulation. 2007 Jan 2;115(1):27-33 [17179016.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 3;99(1):32-40 [17202111.001]
  • [Cites] Epidemiology. 2007 Mar;18(2):213-9 [17235211.001]
  • [Cites] Dement Geriatr Cogn Disord. 2007;23(3):194-201 [17259710.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2):279-84 [17482716.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):393-402 [17681160.001]
  • [Cites] J Invest Dermatol. 2007 Oct;127(10):2323-7 [17522705.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2218-25 [17971519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2226-32 [18006910.001]
  • [Cites] J Natl Cancer Inst. 2008 Jan 16;100(2):134-9 [18182618.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):88-94 [18199714.001]
  • [Cites] Urology. 2008 Jan;71(1):118-22 [18242378.001]
  • [Cites] Am J Med. 2008 Apr;121(4):302-9 [18374689.001]
  • [Cites] Am J Gastroenterol. 2008 Apr;103(4):825-37 [18371146.001]
  • [Cites] Cancer Causes Control. 2008 Sep;19(7):767-74 [18322813.001]
  • [Cites] JAMA. 2000 Jun 28;283(24):3211-6 [10866868.001]
  • [Cites] Arch Intern Med. 2000 Aug 14-28;160(15):2363-8 [10927735.001]
  • [Cites] Arch Dermatol. 2001 Aug;137(8):1055-8 [11493098.001]
  • [Cites] Med Care. 2003 Jun;41(6):761-74 [12773842.001]
  • [Cites] Pharmacotherapy. 2003 Jun;23(6):726-30 [12820814.001]
  • [Cites] Arch Intern Med. 2004 Jan 26;164(2):146-52 [14744837.001]
  • [Cites] Med Care Res Rev. 2003 Sep;60(3 Suppl):92S-123S [15095548.001]
  • [Cites] Am J Cardiol. 2004 May 1;93(9):1124-9 [15110204.001]
  • [Cites] Lancet. 2004 May 15;363(9421):1607-8 [15145635.001]
  • [Cites] Lancet Neurol. 2004 Jun;3(6):369-71 [15157852.001]
  • [Cites] Arch Dermatol. 2004 Sep;140(9):1079-85 [15381547.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Arch Dermatol. 1991 Aug;127(8):1194-7 [1863078.001]
  • [Cites] J Clin Epidemiol. 1993 Oct;46(10):1075-9; discussion 1081-90 [8410092.001]
  • [Cites] Arch Dermatol. 1993 Oct;129(10):1286-90 [8215493.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] Int J Cancer. 1995 Feb 8;60(4):489-94 [7829262.001]
  • [Cites] Arch Dermatol. 1995 Feb;131(2):164-9 [7857112.001]
  • [Cites] J R Soc Med. 1997 Jul;90(7):371-4 [9290417.001]
  • [Cites] JAMA. 1998 May 27;279(20):1615-22 [9613910.001]
  • [Cites] Lancet. 1999 Aug 28;354(9180):723-9 [10475183.001]
  • [Cites] Int J Cancer. 2005 Apr 20;114(4):643-7 [15578694.001]
  • [Cites] N Engl J Med. 2005 Apr 7;352(14):1425-35 [15755765.001]
  • [Cites] N Engl J Med. 2005 May 26;352(21):2184-92 [15917383.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):465-76 [15651087.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(4):CD003697 [16235336.001]
  • [Cites] JAMA. 2005 Nov 16;294(19):2437-45 [16287954.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Dec;5(8):579-94 [16375664.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):74-80 [16391219.001]
  • [Cites] Oncologist. 2006 Mar;11(3):306-15 [16549815.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):682-6 [16496410.001]
  • [Cites] Am J Epidemiol. 2006 Jun 15;163(12):1149-56 [16624967.001]
  • [Cites] JAMA. 2006 Jun 21;295(23):2720-1; author reply 2721-2 [16788122.001]
  • (PMID = 19124815.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00007631
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106592; United States / NCI NIH HHS / CA / R25CA087972; United States / NCI NIH HHS / CA / R01CA106807; United States / NIAMS NIH HHS / AR / R01 AR049342; United States / AHRQ HHS / HS / 5T32HS000011-21; United States / NCI NIH HHS / CA / R01 CA106807; United States / NCI NIH HHS / CA / R25 CA087972; United States / NCI NIH HHS / CA / R01CA106592; United States / AHRQ HHS / HS / T32 HS000011; United States / NIAMS NIH HHS / AR / R01AR49342
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  • [Other-IDs] NLM/ NIHMS507348; NLM/ PMC3771656
  •  go-up   go-down


39. Eyden B, Moss J, Shore I, Banerjee SS: Metastatic small cell malignant melanoma: a case requiring immunoelectronmicroscopy for the demonstration of lattice-deficient melanosomes. Ultrastruct Pathol; 2005 Jan-Feb;29(1):71-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic small cell malignant melanoma: a case requiring immunoelectronmicroscopy for the demonstration of lattice-deficient melanosomes.
  • A case of metastatic malignant melanoma exhibiting small cell morphology is described.
  • The patient had had a previous primary nodular small cell melanoma.
  • Tumor cells were negative for S-100 protein and very focally positive for cytokeratin: these findings in combination with small cell morphology suggested the possibility of small cell carcinoma.
  • This tumor is an uncommon example of malignant melanoma where immunoultrastructural analysis helped clarify the nature of otherwise nondescript granules as true but lattice-deficient melanosomes.
  • This is also the first case of small cell melanoma to be studied by electron microscopy.
  • [MeSH-major] Lymphatic Metastasis / pathology. Melanoma / pathology. Melanosomes / ultrastructure. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / metabolism. Male. Microscopy, Electron, Transmission. Microscopy, Immunoelectron. Neoplasms, Multiple Primary / pathology. S100 Proteins / metabolism. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15931781.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


40. Juten PG, Mureau MA, Hofer SO: [Reconstruction of a cheek defect in three patients]. Ned Tijdschr Geneeskd; 2007 May 19;151(20):1136-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A woman aged 62 and two men aged 52 and 26 all with a cheek defect following resection of a recurrence of a lentigo maligna, a recurrence of a basal-cell carcinoma of the wispy type and a dermatofibrosarcoma protuberans respectively, all underwent cheek reconstruction.
  • The rotation flap technique was used in the first two patients.
  • The third patient was treated with a cervicofacial musculocutaneous transposition flap and underwent postoperative radiotherapy due to the high risk of recurrence.
  • Defects after radical resection of malignant head and neck skin tumours can be treated by several reconstruction techniques depending on the site, size, and shape of the defect.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Dermatofibrosarcoma / surgery. Hutchinson's Melanotic Freckle / surgery. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / surgery. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17557671.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


41. Cho KJ, Lee DH, Kim NG, Kim J: Fibroepithelioma of pinkus on mucocutaneous junction. J Craniofac Surg; 2010 Nov;21(6):1991-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibroepithelioma of Pinkus is a variant form of basal cell carcinoma that clinically presents as a single or multiple red plaques or flesh-colored nodules without ulceration.
  • A 57-year-old male patient presented with a mass at the left nostril, which had first appeared about 10 years earlier.
  • The patient is being monitored for any possible local recurrence.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Nasal Mucosa / pathology. Nose Neoplasms / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119480.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Sidoroff A: [Photodynamic therapy of cutaneous epithelial malignancies. An evidence-based review]. Hautarzt; 2007 Jul;58(7):577-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For Bowen disease and superficial basal cell carcinoma, PDT can be regarded as the first-line non-invasive treatment.
  • In nodular basal cell carcinoma, effectiveness for lesions up to a thickness of 2 mm is well documented.
  • [MeSH-major] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Keratosis / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy. Sunlight / adverse effects
  • [MeSH-minor] Cryotherapy. Evidence-Based Medicine. Humans. Multicenter Studies as Topic. Neoplasm Recurrence, Local / drug therapy. Patient Acceptance of Health Care. Practice Guidelines as Topic. Randomized Controlled Trials as Topic. Time Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cosmet Laser Ther. 2003 Jun;5(2):107-10 [12850802.001]
  • [Cites] J Photochem Photobiol B. 1995 Jul;29(1):53-7 [7472803.001]
  • [Cites] Br J Dermatol. 2001 Sep;145(3):467-71 [11531838.001]
  • [Cites] J Dermatolog Treat. 2002;13 Suppl 1:S19-23 [12060513.001]
  • [Cites] J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):414-8 [10459115.001]
  • [Cites] Acta Derm Venereol. 1999 May;79(3):204-6 [10384917.001]
  • [Cites] Arch Dermatol. 2006 Jun;142(6):729-35 [16785375.001]
  • [Cites] Br J Dermatol. 2002 Apr;146(4):552-67 [11966684.001]
  • [Cites] J Am Acad Dermatol. 2002 Aug;47(2):258-62 [12140473.001]
  • [Cites] Arch Dermatol. 1998 Jul;134(7):821-6 [9681345.001]
  • [Cites] Acta Derm Venereol. 2005;85(6):483-90 [16396794.001]
  • [Cites] J Am Acad Dermatol. 2003 Feb;48(2):227-32 [12582393.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):33-40 [14732657.001]
  • [Cites] Br J Dermatol. 1995 Aug;133(2):282-8 [7547399.001]
  • [Cites] Arch Dermatol Res. 1996 Sep;288(10):561-4 [8919036.001]
  • [Cites] Br J Dermatol. 1994 Jun;130(6):743-51 [8011500.001]
  • [Cites] Br J Dermatol. 2000 Feb;142(2):338-9 [10730770.001]
  • [Cites] Br J Dermatol. 2007 May;156(5):793-801 [17419691.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):17-23 [14732655.001]
  • [Cites] J Dermatolog Treat. 2003 Jun;14(2):99-106 [12775317.001]
  • [Cites] Br J Dermatol. 2000 Oct;143(4):767-72 [11069454.001]
  • [Cites] Br J Dermatol. 2005 Apr;152(4):765-72 [15840111.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1029-36 [17034536.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • [Cites] J Photochem Photobiol B. 1990 Jun;6(1-2):143-8 [2121931.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):41-6 [14732659.001]
  • [Cites] J Drugs Dermatol. 2003 Dec;2(6):629-35 [14711141.001]
  • [Cites] Br J Dermatol. 2000 Dec;143(6):1270-5 [11122032.001]
  • [Cites] Br J Dermatol. 2003 Mar;148(3):539-43 [12653747.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] Br J Dermatol. 1996 Nov;135(5):766-71 [8977678.001]
  • [Cites] J Drugs Dermatol. 2006 Feb;5(2 Suppl):17-25 [16485877.001]
  • [Cites] Arch Dermatol. 2003 Oct;139(10):1313-20 [14568836.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1242-9 [14674903.001]
  • [Cites] Acta Derm Venereol. 2005;85(5):424-8 [16159735.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):196-200 [15270891.001]
  • (PMID = 17522831.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 41
  •  go-up   go-down


43. Onishi K, Maruyama Y, Okada E, Ogino A: Medial canthal reconstruction with glabellar combined Rintala flaps. Plast Reconstr Surg; 2007 Feb;119(2):537-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In medial canthal reconstruction, the continuity of color and texture and the reproduction of natural external appearance are required, and reconstruction with a flap adjacent to the defect is frequently performed as the first choice.
  • RESULTS: Reconstruction by means of this procedure was performed in five patients with defects after resection of medial canthal basal cell carcinoma.
  • No recurrence was observed in any patient, and satisfactory results including aesthetic results were obtained in all patients.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelids / surgery. Forehead / surgery. Reconstructive Surgical Procedures / methods. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17230086.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Banerjee S: Cutaneous manifestations in renal failure patients: a case series. Indian J Dermatol Venereol Leprol; 2007 Mar-Apr;73(2):106-8
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our first case had cutaneous cryptococcosis where skin lesions gave a clue to the diagnosis of altered sensorium and underlying meningitis.
  • The second case initially presented with florid warts and was treated successfully but later presented with an explosive recurrence of skin lesions due to malignant transformation.
  • Our third case had basal cell carcinoma over the presternal region that was successfully treated with liquid nitrogen cryotherapy.
  • To conclude, cutaneous manifestations in patients with renal failure are varied and a high degree of suspicion is needed for early diagnosis and aggressive treatment to effectively combat mortality and morbidity.
  • [MeSH-minor] Acute Kidney Injury / complications. Adolescent. Adult. Carcinoma, Basal Cell / etiology. Condylomata Acuminata / etiology. Cryptococcosis / etiology. Dermatomycoses / etiology. Female. Humans. Kidney Failure, Chronic / complications. Male. Middle Aged. Parapsoriasis / chemically induced. Skin Neoplasms / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17456917.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


45. Ansems TM, van der Pols JC, Hughes MC, Ibiebele T, Marks GC, Green AC: Alcohol intake and risk of skin cancer: a prospective study. Eur J Clin Nutr; 2008 Feb;62(2):162-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the association between total alcohol intake and intake of different types of alcoholic beverages in relation to the risk of basal cell (BCC) and squamous cell (SCC) carcinoma of the skin.
  • CONCLUSIONS: There are no associations between first occurrence of skin cancers and alcoholic beverage consumption.
  • [MeSH-major] Alcohol Drinking. Alcoholic Beverages / adverse effects. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Beer. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / epidemiology. Prospective Studies. Queensland / epidemiology. Risk Factors. Surveys and Questionnaires. Wine

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392700.001).
  • [ISSN] 0954-3007
  • [Journal-full-title] European journal of clinical nutrition
  • [ISO-abbreviation] Eur J Clin Nutr
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


46. González-Alva P, Tanaka A, Oku Y, Yoshizawa D, Itoh S, Sakashita H, Ide F, Tajima Y, Kusama K: Keratocystic odontogenic tumor: a retrospective study of 183 cases. J Oral Sci; 2008 Jun;50(2):205-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis was confirmed by reevaluation of hematoxylin and eosin-stained slides on the basis of the 2005 WHO Classification.
  • Patient age at the time of diagnosis ranged from 6 to 78 years, with a peak in the third decade of life (mean age: 32.8 years).
  • Association with the nevoid basal cell carcinoma syndrome (NBCCS) was found in 6.0% of all tumors, and recurrence was found in 13.1% of patients.
  • We found that tumors that initially appeared in the maxilla alone had a higher recurrence rate than those that first appeared in the mandible alone.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Basal Cell Nevus Syndrome / epidemiology. Child. Female. Humans. Japan / epidemiology. Male. Mandibular Neoplasms / epidemiology. Maxillary Neoplasms / epidemiology. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Retrospective Studies. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18587212.001).
  • [ISSN] 1343-4934
  • [Journal-full-title] Journal of oral science
  • [ISO-abbreviation] J Oral Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


47. Xing X, Xue C, Li J: [Reconstruction of nasal defect after tumor excision]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Jul;21(7):714-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among 428 cases, there were 273 men and 155 women, with a median age of 52 years (12-78 years); including 146 cases of basal cell carcinoma, 83 cases of squamous cell carcinoma, 54 cases of epidermal cyst, and 145 cases of pigmented naevus.
  • The clinical stage of malignant tumor was 0-I stage, the course of disease was 1 week to 3 months.
  • RESULTS: Among 428 cases, 423 cases acquired complete recovery; 3 cases which had epiderm necrosis over the far end of the flap achieved healing by the first intention and 2 cases which had suffered low-grade infection of incision achieved healing by the second intention after regional change dressings.
  • A total of 385 patients were available for follow-up of 1 to 60 months, no tumor recurrence occurred, and the repaired tissue were good match with surrounding tissue, good nasal contour was obtained, the cosmetic results were satisfactory.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Nose Neoplasms / surgery. Rhinoplasty / methods. Skin Neoplasms / surgery. Surgical Flaps
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Wound Healing. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17694661.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


48. Gonçalves JC: Fractional cryosurgery for skin cancer. Dermatol Surg; 2009 Nov;35(11):1788-96
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • First, the center of the lesion is frozen, reducing its size, then this procedure is repeated as necessary until the tumor diameter is smaller than 10 mm, at which point the standard cryosurgical procedure is performed.
  • Eighty-seven basal cell carcinomas (BCCs) and nine squamous cell carcinomas (SCCs) of the face (65 of which were orbital or periocular) measuring between 9 and 45 mm were treated.
  • All SCCs were cured without recurrence.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Cryosurgery / methods. Facial Neoplasms / surgery. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19732116.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Asuquo ME, Ngim O, Ugare G, Omotoso J, Ebughe G: Major dermatologic malignancies encountered in a teaching hospital surgical department in South Nigeria. Am J Clin Dermatol; 2008;9(6):383-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous cell carcinoma (SCC) was the most common (n = 23; 37%), followed by Kaposi sarcoma (KS) [n = 17; 27%].
  • Other malignancies included basal cell carcinoma (BCC), melanoma, and dermatofibrosarcoma protuberans (DFSP) [n = 5; 8% each].
  • The peak age varied with the type of cancer but none was found in patients in the first decade of life.
  • There was a high recurrence rate for DFSP.
  • [MeSH-minor] Africa / epidemiology. African Continental Ancestry Group. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Hospitals, Teaching / statistics & numerical data. Humans. Male. Melanoma / pathology. Melanoma / surgery. Neoplasm Metastasis. Nigeria. Retrospective Studies. Sarcoma, Kaposi / pathology. Sarcoma, Kaposi / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18973404.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


50. Chao Y, Xin X, Jiangping C: Medial canthal reconstruction with combined glabellar and orbicularis oculi myocutaneous advancement flaps. J Plast Reconstr Aesthet Surg; 2010 Oct;63(10):1624-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reconstruction with local flaps adjacent to the defect is often the first-choice treatment option.
  • RESULTS: Reconstruction employing this procedure was performed on 12 patients with defects after resection of a medial canthal basal cell carcinoma.
  • No recurrence was observed in any of the patients, and satisfactory results, including aesthetic results, were obtained for all patients.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Eyelids / surgery. Facial Muscles / surgery. Reconstructive Surgical Procedures / methods. Skin Neoplasms / surgery. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19955033.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


51. Kazakov DV, Vittay G, Michal M, Calonje E: High-grade trichoblastic carcinosarcoma. Am J Dermatopathol; 2008 Feb;30(1):62-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we present the second case of this tumor, which, in contrast to the original example, may be classified as a high-grade neoplasm.
  • The tumor was excised, and the patient had no evidence of recurrence or metastasis 6 years after surgery.
  • Microscopically, the neoplasm demonstrated a fenestrated growth pattern with a slightly myxoid matrix in the background.
  • Two clear components were identified: the first component was clearly epithelial with formation of small round nests, lobules, delicate strands, and small cribriform structures of basaloid cells with some degree of peripheral palisading, nuclear atypia, focal nuclear crowding, and frequent mitotic figures including abnormal forms.
  • We view the present case and that previously reported in 2004 as authentic carcinosarcomas, and not as metaplastic (sarcomatoid) basal cell carcinomas.
  • [MeSH-minor] Aged, 80 and over. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Ear / pathology. Humans. Immunohistochemistry. Male

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212548.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Lung T, Tăşcău OC, Almăşan HA, Mureşan O: Head and neck cancer, treatment, evolution and post therapeutic survival - Part 2: a decade's results 1993-2002. J Craniomaxillofac Surg; 2007 Mar;35(2):126-31
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION AND OBJECTIVES: In the second part of an analysis of a 10-year period of treating oral cancer patients, the focus was the efficiency of treatment, recurrence rates and survival.
  • PATIENTS AND METHODS: From 1485 patients with oral and maxillofacial malignant tumours, 1072 cases could be evaluated.
  • RESULTS: From all patients studied, 811 underwent surgical treatment alone, the mean recurrence rate was 23%.
  • The recurrence rate after surgery plus radiotherapy was 38%; after surgical treatment alone it was 23%; the survival rate at 3 and 5 years post-therapeutically was 49% and 31%, respectively.
  • CONCLUSIONS: The first choice therapy for carcinomas is surgical.
  • The recurrence rate increased with lymph node involvement and tumour size.
  • [MeSH-major] Carcinoma, Basal Cell / mortality. Carcinoma, Squamous Cell / mortality. Head and Neck Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy / methods. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Romania / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449258.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


53. Wu Y, Chai J, Liu C: [Repair of immedicable ulcer in skull cap with expanded bipedical axial flap in senile patients]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Sep;21(9):917-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among them, the causes of disease were trauma in 1 case, infection in 1 case, squamous cell carcinoma in 2 cases, and basal cell carcinoma in 1 case.
  • At first stage, soft tissue expander was implanted under the frontal branch of superficial temporal artery and the musculus frontalis according to preoperative design.
  • No ulcer recurrence and no incompetence in papebral fissure was found.
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / surgery. Graft Survival. Humans. Male. Middle Aged. Reoperation. Wound Healing / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17933221.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


54. Tran MN, Goodwin Jinesh G, McConkey DJ, Kamat AM: Bladder cancer stem cells. Curr Stem Cell Res Ther; 2010 Dec;5(4):387-95
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stem cells are undifferentiated cells that renew themselves while simultaneously producing differentiated tissue- or organspecific cells through asymmetric cell division.
  • The appreciation of the importance of stem cells in normal tissue biology has prompted the idea that cancers may also develop from a progenitor pool (the "cancer stem cell (CSC) hypothesis"), and this idea is gaining increasing acceptance among scientists.
  • CSCs are sub-populations of cancer cells responsible for tumor initiation, differentiation, recurrence, metastasis, and drug resistance.
  • First identified in the hematopoietic system, CSCs have also been discovered in solid tumors of the breast, colon, pancreas, and brain.
  • Recently, the tissue-specific stem cells of the normal urothelium have been proposed to reside in the basal layer, and investigators have isolated phenotypically similar populations of cells from urothelial cancer cell lines and primary tumors.
  • Herein, we review the CSC hypothesis and apply it to explain the development of the two different types of bladder cancer: noninvasive ("superficial") carcinoma and invasive carcinoma.
  • [MeSH-major] Carcinoma / pathology. Neoplastic Stem Cells / pathology. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology. Urothelium / metabolism
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic. Disease Progression. Humans. Models, Biological. Neoplasm Invasiveness. Organ Specificity. Stem Cell Niche

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20955163.001).
  • [ISSN] 2212-3946
  • [Journal-full-title] Current stem cell research & therapy
  • [ISO-abbreviation] Curr Stem Cell Res Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


55. Porta C, Bonomi L, Lillaz B, Klersy C, Imarisio I, Paglino C, Rovati B, Danova M, Ferraris E, Mensi M, Rovereto B: Immunological stress in kidney cancer patients undergoing either open nephrectomy or nephron-sparing surgery: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. Oncol Rep; 2008 Dec;20(6):1511-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunosuppression is a characteristic hallmark of renal cell carcinoma (RCC), with several complex immune defects, almost solely at the level of cell-mediated immune function, well evident even in patients at first diagnosis.
  • The main circulating lymphocyte subsets and the total number of circulating dendritic cells were quantified in 47 RCC patients at diagnosis (T0), 12 h (T1), 24 h (T2) and 8 days following either radical nephrectomy or nephron-sparing surgery using flow cytometry.
  • RCC patients presented, at baseline, (T0) a profound state of immunosuppression involving naïve T-cells, memory T-cells, CD16+ NK and total circulating dendritic cells, that worsened after 12 (T1) and 24 h (T2) from surgery, involving the majority of the analysed subsets; after 8 days (T3) from surgical removal of tumor, however, there was a return of all the analyzed parameters to the basal state.
  • In conclusion, surgery causes transient but relevant immune suppression in RCC patients; even though, by day +8, this tends to return to baseline, immunostimulatory therapies could be considered in the peri-operative setting with the aim of reducing immunosuppression and, hopefully, also disease recurrence.
  • [MeSH-major] Carcinoma, Renal Cell / immunology. Dendritic Cells / metabolism. Immunophenotyping / methods. Kidney Neoplasms / immunology. Kidney Neoplasms / surgery

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19020735.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


56. Dagregorio G, Darsonval V: Post-ablative reconstruction of the medial canthus and medial orbital wall using conchal cartilage graft with three illustrative cases. Br J Plast Surg; 2005 Dec;58(8):1152-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When the medial third of the upper or lower eyelid has to be reconstructed after full-thickness tumour excision, we usually use Hübner tarsomarginal grafts, but when medial canthal lesions spread to the medial orbital wall without invading the orbital margin, conchal graft becomes our first surgical option.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Cartilage / transplantation. Eyelid Neoplasms / surgery. Eyelids / surgery
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Orbit / pathology. Orbit / surgery. Reconstructive Surgical Procedures / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16039629.001).
  • [ISSN] 0007-1226
  • [Journal-full-title] British journal of plastic surgery
  • [ISO-abbreviation] Br J Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Qing Y, Cen Y, Wang H, Liu Y: [Surgical treatment of scalp malignant tumor]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Jan;22(1):59-62
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of scalp malignant tumor].
  • OBJECTIVE: To investigate the effects of different surgical methods in treating scalp malignant tumors.
  • METHODS: From January 1995 to September 2004, 70 patients with scalp malignant tumor were treated with different surgical methods.
  • There were 31 cases of basal cell carcinoma, 24 cases of squamous carcinoma, 8 cases of melanocarcinoma, 4 cases of fibrous sarcoma, 2 cases of liposarcoma, and 1 case of vasculosarcoma.
  • RESULTS: Of 70 cases, 67 skin flaps survived and incision healed by first intention; 2 flaps necrosed at distal part (< 1 cm) and healed by second intention after dressing change; 1 flap infected and was treated with symptomatic medication.
  • All the donor sites healed by first intention.
  • Fifty-five patients were followed up for 1 to 5 years and 5 cases had tumor recurrence.
  • In patients receiving skin transplantation, 1 case of squamous carcinoma and 1 case of fibrous sarcoma relapsed after 1 year and 2.5 years respectively and were given radical resection and skin flap grafting; in patients receiving skin flap grafting, 1 case of vasculosarcoma and 1 case of squamous carcinoma relapsed after 6 months and 3 months respectively, and gave up treatment; 1 case of fibrous sarcoma relapsed after 2 years and was given radical resection and skin flap grafting.
  • The other cases survived and had no tumor recurrence.
  • CONCLUSION: Scalp malignant tumors should be diagnosised and treated as early as possible.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Scalp. Skin Neoplasms / surgery. Skin Transplantation / methods. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18361240.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


58. Lee SY, Jung SN, Sohn WI, Kwon H, Yoo G: Submuscular fibrolipoma of the forehead. J Craniofac Surg; 2010 Nov;21(6):1993-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the first case of a 65-year-old man with a submuscular fibrolipoma of the forehead that showed no evidence of recurrence after excision.
  • [MeSH-major] Facial Muscles / pathology. Forehead / pathology. Lipoma / diagnosis. Muscle Neoplasms / diagnosis
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / pathology. Facial Neoplasms / pathology. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neoplasms, Second Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119481.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


59. Nasir S, Aydin MA: Versatility of free SCIA/SIEA flaps in head and neck defects. Ann Plast Surg; 2010 Jul;65(1):32-7
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This was their first choice over other free flaps due to its versatile advantages.
  • [MeSH-minor] Adenocarcinoma / surgery. Adolescent. Adult. Aged. Bone Transplantation. Burns / surgery. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Child. Cicatrix / surgery. Facial Neoplasms / surgery. Female. Follow-Up Studies. Humans. Male. Maxilla / surgery. Maxillary Neoplasms / surgery. Middle Aged. Neck Injuries / surgery. Neoplasm Recurrence, Local / surgery. Reoperation. Scalp / surgery. Skin Neoplasms / surgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20574218.001).
  • [ISSN] 1536-3708
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Debure C: [Etiological diagnosis of leg ulcers]. Rev Prat; 2010 Sep 20;60(7):966-9
MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Etiological diagnosis of leg ulcers].
  • Etiological diagnosis of leg ulcers must be the first step of treatment, even if we know that veinous disease is often present.
  • This diagnosis helps to choose the right treatment in order to cure even the oldest venous ulcers.
  • Educational programs should be improved to prevent recurrence.
  • [MeSH-minor] Carcinoma, Basal Cell / diagnosis. Cell Transformation, Neoplastic. Diagnosis, Differential. Humans. Risk Factors. Severity of Illness Index. Skin Neoplasms / diagnosis. Treatment Outcome. Wound Healing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21033496.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


61. Cózar MP, Ferrer-Rebolleda J, Redal MC, Moreno A, Tortajada L, Casáns I, Romero C: [Sentinel lymph node biopsy in cutaneous non-melanoma malignancies]. Rev Esp Med Nucl; 2006 Jan-Feb;25(1):10-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first drainage station visualized was considered the sentinel node (SLN).
  • Histopathological analysis of the SLN showed non metastatic disease and none patient developed metastases or local recurrence in the monitoring period.
  • [MeSH-major] Lymphatic Metastasis / diagnosis. Sentinel Lymph Node Biopsy. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma / diagnosis. Carcinoma / radionuclide imaging. Carcinoma / secondary. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / radionuclide imaging. Carcinoma, Basal Cell / secondary. Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / radionuclide imaging. Carcinoma, Merkel Cell / secondary. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / secondary. Child. Dermatofibrosarcoma / diagnosis. Dermatofibrosarcoma / radionuclide imaging. Dermatofibrosarcoma / secondary. False Negative Reactions. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Retrospective Studies. Technetium Tc 99m Aggregated Albumin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540005.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Technetium Tc 99m Aggregated Albumin; 0 / technetium Tc 99m nanocolloid
  •  go-up   go-down


62. Li LF, Zhou SH, Zhao K, Wang SQ, Wu QL, Fan J, Cheng KJ, Ling L: Clinical significance of FDG single-photon emission computed tomography: Computed tomography in the diagnosis of head and neck cancers and study of its mechanism. Cancer Biother Radiopharm; 2008 Dec;23(6):701-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of FDG single-photon emission computed tomography: Computed tomography in the diagnosis of head and neck cancers and study of its mechanism.
  • BACKGROUND: The metabolic changes of malignant cells are earlier than these of morphology. (18)F-fluorodeoxyglucose (FDG) single-photon emission computed tomography (SPECT)-computed tomography (CT) systems provide functional and anatomic images that could significantly improve its diagnostic capability.
  • In this study, we, therefore, investigated in patients with head and neck carcinoma (HNC) the relationship between tumor FDG accumulation and the mRNA expression and protein expression of Glut-1 and Glut-3.
  • CONCLUSIONS: (18)F-FDG SPECT-CT can be as a prospective tool that can judge the malignancy or benignity of head and neck tumor, stage and classify the tumor, distinguish recurrence or necrosis or fibrosis of the tumor after treatment by surgery or radiotherapy, and detect unknown primary tumor.
  • Glut-1 may largely mediate basal glucose transport in HNC cells.
  • [MeSH-major] Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Head and Neck Neoplasms / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed, Single-Photon

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317609.001).
  • [ISSN] 1557-8852
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / Glucose Transporter Type 3; 0 / Radiopharmaceuticals; 0 / SLC2A1 protein, human; 0 / SLC2A3 protein, human; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


63. Escaff S, Fernández JM, González LO, Suárez A, González-Reyes S, González JM, Vizoso FJ: Study of matrix metalloproteinases and their inhibitors in prostate cancer. Br J Cancer; 2010 Mar 2;102(5):922-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Extracellular matrix metalloproteases (MMPs) have raised an extraordinary interest in cancer research because of their potential role in basal membrane and extracellular matrix degradation, consequently facilitating tumour invasion and metastases development.
  • More than 2600 determinations on cancer specimens from 133 patients with clinically localised prostate carcinoma, 20 patients with prostatic intraepithelial neoplasia and 50 patients with benign prostate hyperplasia and controls, were performed.
  • Dendogram shows a first-order division of tumours into two distinct MMPs/TIMPs molecular profiles, one of them with high MMPs/TIMs expression profile (n=70; 52.6%).
  • Tumours with high expression of MMP-11 or -13, or cluster thereof, were significantly associated with higher probability of biochemical recurrence.
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Follow-Up Studies. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis. Survival Rate. Tissue Array Analysis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Dermatol. 1999 Mar;24(2):122-6 [10233668.001]
  • [Cites] J Clin Invest. 1999 May;103(9):1237-41 [10225966.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):21-8 [15630412.001]
  • [Cites] Urol Res. 2005 Feb;33(1):44-50 [15517230.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1173-86 [15793297.001]
  • [Cites] Thromb Haemost. 2005 Apr;93(4):770-8 [15841326.001]
  • [Cites] Cancer Cell. 2005 May;7(5):485-96 [15894268.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):215-27 [15947098.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2171-80 [15928670.001]
  • [Cites] J Clin Pathol. 2005 Jul;58(7):673-84 [15976331.001]
  • [Cites] Prog Urol. 2005 Apr;15(2):250-4 [15999602.001]
  • [Cites] Crit Rev Immunol. 2005;25(6):493-523 [16390324.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2A):973-82 [16619495.001]
  • [Cites] Clin Exp Metastasis. 2006;23(7-8):335-44 [17136575.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):903-11 [17342087.001]
  • [Cites] Neoplasia. 2007 Apr;9(4):349-57 [17460779.001]
  • [Cites] Am J Pathol. 2007 Jun;170(6):2100-11 [17525276.001]
  • [Cites] Br J Cancer. 2007 Oct 8;97(7):957-63 [17848954.001]
  • [Cites] J Biol Chem. 2008 Mar 7;283(10):6232-40 [18174174.001]
  • [Cites] Int J Oncol. 2008 Apr;32(4):757-65 [18360703.001]
  • [Cites] Oncology. 2008;75(3-4):230-6 [18852494.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]
  • [Cites] Int J Cancer. 2000 Mar 20;89(2):118-21 [10756061.001]
  • [Cites] Hum Pathol. 2000 Jul;31(7):860-5 [10923925.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4823-30 [11156241.001]
  • [Cites] J Cell Sci. 2001 Jan;114(Pt 1):111-118 [11112695.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1022-8 [11221828.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2189-93 [11280785.001]
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1076-83 [11308257.001]
  • [Cites] Neoplasia. 2001 Nov-Dec;3(6):459-68 [11774028.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2245-52 [11948407.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):723-8 [12090420.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):657-72 [12209155.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):68-75 [12538453.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(1):15-26 [12664060.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):309-16 [12949813.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(3):217-22 [12970724.001]
  • [Cites] Clin Exp Metastasis. 2003;20(6):541-7 [14598888.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8511-5 [14679018.001]
  • [Cites] Breast Cancer Res. 2004;6(1):R24-30 [14680497.001]
  • [Cites] Am J Pathol. 2004 Apr;164(4):1131-9 [15039201.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1187-92 [15138554.001]
  • [Cites] Cancer Cell. 2004 May;5(5):409-10 [15144947.001]
  • [Cites] Nature. 1990 Dec 20-27;348(6303):699-704 [1701851.001]
  • [Cites] J Biol Chem. 1994 Jun 17;269(24):16766-73 [8207000.001]
  • [Cites] In Vivo. 1994 May-Jun;8(3):439-43 [7803731.001]
  • [Cites] Int J Cancer. 1996 Dec 20;69(6):448-51 [8980245.001]
  • [Cites] J Biol Chem. 1997 Mar 21;272(12):7608-16 [9065415.001]
  • [Cites] Crit Rev Oncol Hematol. 1997 May;26(1):43-53 [9246540.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):96-101 [9495366.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):721-8 [9502414.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6845-52 [9862716.001]
  • [Cites] J Biol Chem. 1999 Mar 12;274(11):6935-45 [10066747.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2004;7(4):327-32 [15356679.001]
  • (PMID = 20160732.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tissue Inhibitor of Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC2833257
  •  go-up   go-down


64. Spinelli HM, Tabatabai N, Muzaffar AR, Isenberg JS: Upper lip reconstruction with the alar crescent flap: A new approach. J Oral Maxillofac Surg; 2006 Oct;64(10):1566-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant etiologies were responsible for the defect in all patients.
  • There was no recurrence of disease in the 20 patients who underwent resection of malignancy.
  • Furthermore, for those same reasons, this procedure is a good first choice in the elderly.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / rehabilitation. Cheek / surgery. Facial Muscles / transplantation. Female. Humans. Lip Neoplasms / rehabilitation. Male. Melanoma / rehabilitation. Middle Aged

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982318.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Levendag PC, Nijdam WM, van Moolenburgh SE, Tan L, Noever I, van Rooy P, Mureau MA, Jansen PP, Munte K, Hofer SO: Interstitial radiation therapy for early-stage nasal vestibule cancer: a continuing quest for optimal tumor control and cosmesis. Int J Radiat Oncol Biol Phys; 2006 Sep 1;66(1):160-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total dose is 44 Gy: 2 fractions of 3 Gy per day, 6-hour interval, first and last fraction 4 Gy.
  • The neck was not treated electively; no neck recurrence in follow-up was seen.
  • [MeSH-major] Brachytherapy / methods. Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Esthetics. Nose Neoplasms / radiotherapy
  • [MeSH-minor] Female. Health Care Costs. Humans. Male. Nasal Cavity. Neoplasm Staging. Photography

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16839706.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Dessy LA, Figus A, Fioramonti P, Mazzocchi M, Scuderi N: Reconstruction of anterior auricular conchal defect after malignancy excision: revolving-door flap versus full-thickness skin graft. J Plast Reconstr Aesthet Surg; 2010 May;63(5):746-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Wider excision and immediate reconstruction are required to reduce the risks of recurrence of the disease, cartilage infection and external ear distortion.
  • RD flap should be considered as the first choice for reconstruction of anterior auricular conchal defects following wider excision of skin tumours.
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Humans. Male. Melanoma / pathology. Melanoma / surgery. Middle Aged. Neoplasm Staging. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009. Published by Elsevier Ltd.
  • (PMID = 19357009.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  •  go-up   go-down


67. Sedghizadeh PP, Wong D, Shuler CF, Linz V, Kalmar JR, Allen CM: Multifocal calcifying epithelial odontogenic tumor. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Aug;104(2):e30-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The calcifying epithelial odontogenic tumor (CEOT), or Pindborg tumor, is a rare and benign odontogenic neoplasm that affects the jaw.
  • For example, multiple odontogenic keratocysts are the most common feature of the inherited condition known as nevoid basal cell carcinoma syndrome.
  • This case, however, is the first one to demonstrate that there may be a multifocal variant of CEOT that has not been previously recognized.
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Rare Diseases

  • Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17630096.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Stafanous SN: The switch flap in eyelid reconstruction. Orbit; 2007 Dec;26(4):255-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: Eight cases of large full-thickness eyelid defects resulting from excision of tumours such as basal cell carcinoma (bcc), squamous cell carcinoma (scc) and sebaceous gland carcinoma (sgc) were taken for repair using the switch flap technique.
  • The patients were followed up frequently in the first few weeks according to need, at six months, and then every year for five years before discharge.
  • At these visits, contour of lid, condition of wound, cornea and donor site were examined for infection, dehiscence, corneal ulcer, notching, trichiasis, and recurrence.
  • RESULTS: Out of the eight cases of eyelid defects, one was from squamous cell carcinoma, three were from sebaceous gland carcinoma, and four were from infiltrative basal cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097963.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Tschen EH, Wong DS, Pariser DM, Dunlap FE, Houlihan A, Ferdon MB, Phase IV ALA-PDT Actinic Keratosis Study Group: Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol; 2006 Dec;155(6):1262-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AKs are believed to progress to in situ squamous cell carcinoma (SCC) and potentially, to invasive SCC.
  • This study seeks to characterize further the efficacy and safety of ALA-PDT by extending previous work to: (i) assess the long-term recurrence rate of AKs that have resolved after ALA-PDT;.
  • The target AK lesions in the per-protocol population clearing completely in the first and second months following a single ALA-PDT treatment (baseline) were 76% and 72%, respectively.
  • The overall recurrence rate for all lesions that were noted to be cleared at some visit during the 12-month period was 24% (162/688).
  • With respect to the lesions biopsied, 91% (127/139) were diagnosed histopathologically as AK, with the balance of lesions being SCC (nine of 139: 7%), basal cell carcinoma (one of 139: 0.7%) and other non-AK diagnoses (two of 139: 1%).
  • The recurrence rate for histologically confirmed AKs was 19%.
  • The clinical diagnosis of AK by investigators appeared to be accurate, with 91% (200/220) of the untreated clinically diagnosed AK lesions being histopathologically confirmed to be AK (AK, 142/220: 65%; advanced AK, 29/220: 13%; macular AK, 29/220: 13%).
  • CONCLUSIONS: ALA-PDT was shown to be an effective and safe therapy for the treatment of AKs of the face and scalp in skin types I-V, with an acceptable rate of recurrence over 12 months of histologically confirmed AKs of 19%.

  • MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107399.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase IV; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down






Advertisement